4//SEC Filing
CoLucid Pharmaceuticals, Inc. 4
Accession 0000911916-17-000026
CIK 0001348649operating
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 4:24 PM ET
Size
4.9 KB
Accession
0000911916-17-000026
Insider Transaction Report
Form 4
Dallas Matthew D
Chief Financial Officer
Transactions
- Sale
Common Stock
2017-01-03$36.25/sh−1,473$53,396→ 40,128 total
Footnotes (1)
- [F1]Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.
Documents
Issuer
CoLucid Pharmaceuticals, Inc.
CIK 0001348649
Entity typeoperating
Related Parties
1- filerCIK 0001348649
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 4:24 PM ET
- Size
- 4.9 KB